Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04528004
Other study ID # STUDY00007432
Secondary ID 1R01HL144937-01A
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date September 26, 2020
Est. completion date July 31, 2025

Study information

Verified date July 2023
Source University of Washington
Contact Laura Curtin
Phone 206-616-6432
Email LCurtin@Cardiology.washington.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Preliminary animal studies by ourselves and others suggest that the dietary supplement, nicotinamide riboside (NR), may improve cardiac function in heart failure (HF) by increasing cellular levels of its metabolite, nicotinamide adenine dinucleotide (NAD+, NADH). This Study will address a key gap in current knowledge by assessing the mechanisms through which raising blood and myocardial NAD+ levels in humans mediates changes in mitochondrial function, protein and epigenetic modifications, as well as inflammation. Human myocardium will be obtained after 4-14 days of oral NR supplementation from advanced heart failure patients undergoing elective left ventricular assist device (LVAD) implantation. Positive results would provide evidence to proceed with further studies of NR as a mitochondria-targeted metabolic therapy in heart failure.


Description:

To definitively demonstrate the effects of increasing NAD+ levels in HF patients, this randomized, placebo-controlled trial of NR in 40 participants scheduled for elective LVAD surgery with the underlying hypotheses that those randomized to NR will have higher myocardial NAD+ levels, improved mitochondrial function, restored gene expression and reduced inflammatory response as compared to participants randomized to placebo. To this end, the study has the following specific aims: Aim 1: Randomize 40 participants undergoing elective LVAD placement into a double-blind, placebo-controlled study of NR vs. placebo at an NR:placebo ratio of 2:1. 1. Participants will have labs (including safety panels) drawn at baseline (Day 1), with NR or placebo dose escalation to 1000mg twice daily by Day 3, and the last dose administered the evening prior to surgery. 2. Final labs will be drawn on the day of surgery, and samples of fresh cardiac tissue removed from the left ventricular apex during LVAD implantation surgery will be collected in the operating room. Aim 2: Determine the effect of NR vs. placebo on NAD(H) levels, mitochondrial function and its regulation through epigenetic modifications in the failing myocardium. 1. Measure NAD+ and NADH levels in the blood and myocardium of the participants. 2. Assess mitochondrial morphology and function in cardiac tissue using electron microscopy (EM) and isolated mitochondria. 3. Determine changes in protein acetylation in the mitochondrial and non-mitochondrial compartments and in nuclear gene regulation. Aim 3: Test the hypothesis that NR improves mitochondrial function and reduces inflammatory response in HF patients. 1. Measure mitochondrial function in peripheral blood mononucleated cells (PBMC). 2. Determine the inflammatory response in PBMC from NR-treated vs. placebo participants. 3. Compare effects on the circulating inflammasome vs. myocardial inflammation.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date July 31, 2025
Est. primary completion date March 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. End-stage heart failure due to ischemic or non-ischemic cardiomyopathy a. If implanted for destination therapy indication, must have New Your Heart Association (NYHA) Class IV Heart Failure AND left ventricular ejection fraction (LVEF) <25% OR maximum minute consumption of oxygen (VO2) <14 OR on requirement for continuous intravenous inotropes 2. Meet clinical and socioeconomic screening criteria for elective LVAD implantation by the University of Washington Mechanical Circulatory Support Program 3. Scheduled (or soon to be scheduled) for elective LVAD implantation 4. Age >18 years Exclusion Criteria: 1. End-stage heart failure due to causes other than ischemic or non-ischemic cardiomyopathy (e.g., valvular, hypertrophic or infiltrative cardiomyopathies). 2. Disease that disqualifies from consideration for LVAD implantation by the University of Washington program: 1. Cirrhosis as evidenced by liver biopsy 2. Irreversible, severe renal disease (estimated glomerular filtration rate (eGFR) <30) or on chronic dialysis 3. Untreated thyroid disease (hyper- or hypo-thyroidism) 4. Severe complications of diabetes, such as diabetes-related amputation, severe retinopathy, peripheral neuropathy or diabetic renal disease (eGFR <30) 3. Tissue physiology or other factors that, in the opinion of the Cardiac Surgeons, make the patient at unacceptably high risk for adverse outcomes. 4. Non-compliance with current treatments, including failure to follow prescribed therapies, such as medications, clinic visits, diagnostic testing and behavioral contracts 5. Active use/abuse of illicit substances 6. Lack of adequate caregiver support to help patient manage LVAD 7. Known allergies to niacin, nicotinamide or warfarin 8. Inability to perform Study visits or procedures 9. Unwillingness/inability to provide informed consent. 10. Participants considered by the attending cardiologist and/or the investigator to be unsuitable for the study

Study Design


Intervention

Drug:
Nicotinamide riboside
Nicotinamide riboside 250mg capsules
Other:
Placebo
Matching placebo 250mg capsules

Locations

Country Name City State
United States University of Washington Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
University of Washington National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Correlations of whole blood NAD+ levels with secondary outcome measures Analyses of correlations of whole blood NAD+ levels and their changes with each of the secondary outcome measures in the NR-treated group Up to 14 days
Other Correlations of myocardial NAD(H) levels with secondary outcome measures Analyses of correlations of myocardial NAD(H) levels and their changes with secondary outcome measures in the NR-treated group Up to 14 days
Primary Between-group comparisons of whole blood NAD+ levels Comparisons of whole blood NAD+ levels on the Day of LVAD Surgery in participants randomized to NR vs. placebo Up to 14 days
Secondary Between-group comparisons of myocardial NAD(H) levels Comparisons of myocardial NAD(H) levels in participants randomized to NR vs. placebo Up to 14 days
Secondary Between-group comparisons of myocardial mitochondrial respiratory function. Comparisons of myocardial mitochondrial respiration in participants randomized to NR vs. placebo Up to 14 days
Secondary Between-group comparisons of myocardial mitochondrial morphology. Comparisons of myocardial mitochondrial morphology, by electron microscopy, in participants randomized to NR vs. placebo Up to 14 days
Secondary Between-group comparisons of myocardial protein acetylation Comparisons of myocardial protein acetylation in participants randomized to NR vs. placebo Up to 14 days
Secondary Between-group comparisons of myocardial gene expression by RNA-seq and the myocardial epigenome by ATAC-seq Comparisons, NR vs. placebo-treated participants, of myocardial gene expression by RNA sequencing (RNA-seq) and the myocardial epigenome by the Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq) Up to 14 days
Secondary Between-group comparisons of inflammatory markers in blood Comparisons, in patients randomized to NR vs. placebo of: 1) plasma levels of highly-sensitive C-reactive protein, interleukin-1beta, interleukin-6, interleukin-18, tumor necrosis factor-alpha, and NLR family pyrin domain containing 3 (NLRP3), as well as 2) mRNA expression of these cytokines in isolated peripheral blood mononuclear cells Up to 14 days
Secondary Between-group comparisons of inflammatory markers in myocardium Comparisons by quantitative morphometry of immunohistochemical staining of macrophages (including M1 and M2 phenotypes) in myocardium in participants randomized to NR vs. placebo Up to 14 days
See also
  Status Clinical Trial Phase
Withdrawn NCT03227393 - The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG N/A
Recruiting NCT04703842 - Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction Phase 1/Phase 2
Recruiting NCT04522609 - Electrostimulation of Skeletal Muscles in Patients Listed for a Heart Transplant N/A
Completed NCT05475028 - Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
Not yet recruiting NCT06240403 - Digoxin and Senolysis in Heart Failure and Diabetes Mellitus Phase 2
Not yet recruiting NCT05988749 - Digital Remote Home Monitoring for Heart Failure N/A
Recruiting NCT04950218 - The Psoriasis Echo Study
Suspended NCT04701112 - Acute Hemodynamic Effects of Pacing the His Bundle in Heart Failure N/A
Completed NCT03305692 - ECG Belt vs. Echocardiographic Optimization of CRT N/A
Recruiting NCT05933083 - MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation N/A
Enrolling by invitation NCT03903107 - The Fluoroless-CSP Trial Using Electroanatomic Mapping N/A
Withdrawn NCT04872959 - TRANSFORM Heart Failure With Reduced Ejection Fraction N/A
Completed NCT02920918 - Treatment of Diabetes in Patients With Systolic Heart Failure Phase 4
Completed NCT02334891 - Kyoto Congestive Heart Failure Study
Recruiting NCT03553303 - Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin Phase 4
Recruiting NCT04083690 - Multi-lead ECG to Effectively Optimize Resynchronization Devices: New CRT Recipients N/A
Recruiting NCT03830957 - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker N/A
Recruiting NCT06121323 - Physiological Effects of Lactate in Individuals With Chronic Heart Failure N/A
Completed NCT03351283 - Effect of Sodium Intake on Brain Natriuretic Peptide Levels in Patients With Heart Failure N/A
Recruiting NCT02960685 - Telesonography for Visually Estimating Ejection Fraction N/A